Epilepsy

Perampanel (FYCOMPA) has been approved for patients aged 4 years or older, who suffer from partial-onset seizures with or without secondarily generalized seizures, as both a tablet and oral suspension formulation.

Bridge the Gap – SYNGAP Education and Research Foundation presented Texas Children’s Hospital with their first research grant of $25,000.

The FDA has granted a tentative approval to Aquestive Therapeutics, Inc.’s clobazam (Sympazan) oral film for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients 2 years of age or older.

Stem cell research from the University of Michigan reveals dangerous cardiac effects of a gene mutation in patients with Dravet syndrome.

Stiripentol (Diacomit) has been approved for treatment in patients 2 years of age and older with Dravet syndrome, a rare form of epilepsy.

The FDA has approved stiripentol (Diacomit) for the treatment of seizures associated with Dravet syndrome, a rare form of epilepsy.

If approved in early 2019, the nasal spray would become the first approved therapy indicated for seizure clusters in 17 years.

Holidays and special events can cause increased likelihood of status epilepticus, possibly due to alcohol consumption and withdrawal, changes in sleep patterns, and non-compliance with anti-seizure drugs.

The phase 3 trial evaluating ZX008 as a treatment for Dravet syndrome met its primary endpoint.

The newly-revealed structure of the neurotransmitter GABAA, a γ-aminobutyric acid, opens new possibilities for drugs to treat epilepsy, anxiety, and insomnia.

Converting from brand-name levetiracetam to generic version does not greatly increase seizure frequency among patients with epilepsy.

Cannabidiol (Epidiolex) is the first drug containing a marijuana-derived substance to receive FDA approval.

The new findings also show that the premature activation of synapses can be prevented by AMPA receptor antagonist therapy.

The supplemental New Drug Application for perampanel (Fycompa) expands the indication to include pediatric patients 2-12 years of age.

The zEEG provides clinicians and patients with an EEG system that is simple, easy and convenient that benefits with a quick and smart analysis of data through a cloud platform.

The FDA will come to a conclusion on whether to approve Epidiolex in late June and if approved, this will be the first cannabis-based product to become FDA approved.

Approval provides pediatric epilepsy patients a treatment option to be administered at a therapeutic dose from day 1/

EpiFinder, a mobile health application, predicted either an epilepsy syndrome or alternative diagnosis with 86.8% accuracy.

The 7-year data showed the median seizure frequency reduction of 75% in those with drug-resistant epilepsy with partial-onset seizures receiving DBS therapy.

Monthly seizures were reduced by about 40% in those taking Epidiolex.

It is the first pharmacologic therapy approved in the United States for TSC, a rare genetic disorder that impacts roughly 50,000 patients in the US.

Phenobarbital’s reputation among physicians and patients is aided by its history — its century-plus usage as an anticonvulsant lends to the notion that it’s a safer option. It may not be.

The Embrace smartwatch allows patients with epilepsy to monitor for seizure activity without wearing an EEG

Zogenix announced that the last patient has been randomized into the treatment period of Study 1504, its second Phase 3 clinical trial evaluating ZX008 in Dravet syndrome.

Single-slice GluCEST has been shown to lateralize and localize epileptogenic regions of the hippocampus on 7 Tesla MRI in MRI-negative patients.

Maternal mortality for women with epilepsy is considerably higher than for women without the condition, according to new data.

More than half of patients on the epilepsy therapy remained on the treatment after 24 months.

An open-label study of ganaxolone has shown that the therapy is capable of reducing the frequency of seizures and increasing the number of seizure-free days in young patients.

In total, 77% of patients that underwent the surgery were free from seizures at 1 year, compared to 7% in the medication-only group.

SenTiva is capable of detecting and responding to seizures in patients — before they even begin.